Business Wire

SOSAFE

24.5.2023 08:01:30 CEST | Business Wire | Press release

Share
SoSafe Adds Two US Cybersecurity Luminaries to Its Board Amidst Rapid Go-to-market Expansion

SoSafe, Europe’s leading vendor for security awareness and training, today announced it has appointed two world-class cybersecurity industry leaders to its board: Tech executive Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, and Bhagwat Swaroop, experienced executive in the cybersecurity space and current President of Digital Security Solutions at Entrust.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005033/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Europe’s leading security awareness and training vendor SoSafe adds Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, to their board. (Photo: Business Wire)

Niklas Hellemann, CEO of SoSafe: “At SoSafe, we are at the forefront of security awareness innovation. Bringing two world-class industry leaders like Zeynep and Bhagwat for our board will strengthen our market expertise even further, boosting international expansion and product excellence. Advances in generative AI will inevitably lead to an escalation of the cyber threat landscape, particularly from a human risk perspective. We are delighted to welcome two highly experienced cybersecurity experts to our board, helping us to navigate this paradigm shift. SoSafe’s whole management team is very much looking forward to working with them.”

Zeynep Inanoglu Ozdemir has held key marketing leadership roles at Palo Alto Networks during a four-year period of rapid growth and transformation. As CMO, she has been responsible for launching an award-winning brand campaign for the company as well as pioneering the XDR category in cybersecurity at large. Previously, Ozdemir has worked at Palantir Technologies and Google, and currently sits on the board at iKSV, Turkey’s predominant arts and culture foundation. She holds a PhD in speech processing from Cambridge University, Machine Intelligence Lab, and a bachelor's degree in electrical engineering from Harvard University. Her deep expertise in category creation, data-driven marketing and growth strategies will be of great value to our board at SoSafe.

“Human-level risk management and security awareness programs are key capabilities in an increasingly automated threat landscape”, says Ozdemir. “I am very excited work with SoSafe to further their mission to drive secure behavior at scale.”

Bhagwat Swaroop is the President of Digital Security Solutions at Entrust and brings more than 20 years of leadership experience driving growth in global high-tech companies to the board. He was most recently president and General Manager of One Identity, where he led the company’s turnaround to a cloud-based cybersecurity company. Prior to One Identity, Swaroop was a Corporate Officer and Executive Vice President at Proofpoint responsible for driving company’s rapid growth and helped make Proofpoint the market leader in email security. Previously he held leadership positions at Symantec, NetApp, McKinsey, and Intel. He is a seasoned strategic leader and brings a deep understanding of the enterprise security landscape, technology ecosystem and cloud driven business models. He is a sought expert and public speaker on cybersecurity, cloud computing and national policy topics. “Security awareness training has become a foundational capability to make the human layer more resilient to the constant phishing attempts.” states Swaroop. “I was impressed by SoSafe’s deep focus on fusing behavioral science with cybersecurity awareness solutions. I am looking forward to working with the SoSafe leadership team in the next phase of their growth journey”.

With these new additions to its board, European security awareness leader SoSafe underlines its commitment for international expansion and product innovation.

_______________

About SoSafe

SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 3000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.

Website: www.sosafe-awareness.com/

LinkedIn: https://www.linkedin.com/company/sosafe-cyber-security/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005033/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye